Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.34 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.34 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6071368 | 0.86 | OPRM1 (0.45) | OPRM1GRIN1GRIN2ANPY5RHTR2A | |
| Methyl Alcohol SCHEMBL8153725 | 0.84 | OPRM1 (0.41) | OPRM1GRIN1GRIN2AHTR2AOPRL1 | |
| SCHEMBL27306600 | 0.80 | OPRM1 (0.43) | OPRM1GRIN1GRIN2AHTR2AGRIN2B | |
| SCHEMBL4780555 | 0.75 | OPRM1 (0.50) | OPRM1MEN1KMT2ANPY5RHTR2A | |
| Methyl Alcohol SCHEMBL8520431 | 0.74 | OPRM1 (0.45) | OPRM1NPY5RHTR2AOPRL1OPRK1 | |
| SCHEMBL15995122 | 0.67 | OPRM1 (0.42) | OPRM1GRIN1GRIN2AHTR2AOPRL1 | |
| SCHEMBL15995119 | 0.67 | OPRM1 (0.42) | OPRM1GRIN1GRIN2AHTR2AOPRL1 | |
| SCHEMBL1958095 | 0.67 | OPRM1 (0.57) | OPRM1MEN1KMT2ANPY5RTACR1 | |
| SCHEMBL21312268 | 0.67 | OPRM1 (0.42) | OPRM1GRIN1GRIN2AHTR2AOPRL1 | |
| SCHEMBL8221130 | 0.67 | TACR1 (0.47) | OPRM1MEN1KMT2AGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796660-B2 | Gamma amino acid building blocks | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2017-10-24 | — | — | US | disclosed |
| US-20160280632-A1 | GAMMA AMINO ACID BUILDING BLOCKS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2016-09-29 | — | — | US | disclosed |
| US-9382291-B2 | Gamma amino acid building blocks | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150148523-A1 | GAMMA AMINO ACID BUILDING BLOCKS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2015-05-28 | — | — | US | disclosed |
| US-8664356-B2 | Gamma amino acid building blocks | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-03-04 | — | — | US | disclosed |
| US-20110118440-A1 | GAMMA AMINO ACID BUILDING BLOCKS | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2011-05-19 | — | — | US | disclosed |
| WO-2011047190-A1 | GAMMA AMINO ACID BUILDING BLOCKS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118440-A1 | GAMMA AMINO ACID BUILDING BLOCKS | DNPEP, QPCT, ANPEP | OPRM1 2600/4885MEN1 2012/4885KMT2A 3578/4885 |
| US-20150148523-A1 | GAMMA AMINO ACID BUILDING BLOCKS | DNPEP, QPCT, ANPEP | OPRM1 2600/4885MEN1 2012/4885KMT2A 3578/4885 |
| US-20160280632-A1 | GAMMA AMINO ACID BUILDING BLOCKS | DNPEP, QPCT, ANPEP | OPRM1 2600/4885MEN1 2012/4885KMT2A 3578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.